×

Piperidin-4-yl azetidine derivatives as JAK1 inhibitors

  • US 9,999,619 B2
  • Filed: 10/07/2016
  • Issued: 06/19/2018
  • Est. Priority Date: 03/10/2010
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating graft versus host disease in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound, which is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×